Scavenger receptor BI is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles

Theranostics

Volumn 3, Issue 7, 2013, Pages 477-486

  Zheng, Ying ^a,b   Liu, Yanyan ^c   Jin, Honglin ^a,b   Pan, Shaotao ^a,b   Qian, Yuan ^a,b   Huang, Chuan ^a,b   Zeng, Yixin ^c   Luo, Qingming ^a,b   Zeng, Musheng ^c   Zhang, Zhihong ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Biomarker; Cancer theranostics; Lipoprotein nanocarrier; Nasopharyngeal carcinoma; SR B1

Indexed keywords

ANTINEOPLASTIC AGENT; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN MIMICKING PEPTIDE PHOSPHOLIPID SCAFFOLD; MOLECULAR SCAFFOLD; NANOPARTICLE; PLACEBO; SCAVENGER RECEPTOR BI; UNCLASSIFIED DRUG; PEPTIDE; SCARB1 PROTEIN, HUMAN; SCAVENGER RECEPTOR B; TUMOR MARKER; BIOLOGICAL MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL DEATH; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR BIOPSY; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHEMISTRY; GENETICS; METABOLISM; NASOPHARYNGEAL NEOPLASMS; NUDE MOUSE; PATHOPHYSIOLOGY; CANCER THERANOSTICS; DRUG ANTAGONISM; LIPOPROTEIN NANOCARRIER.; NASOPHARYNX TUMOR; SR-B1;

ANIMALS; CELL PROLIFERATION; FEMALE; HUMANS; LIPOPROTEINS, HDL; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NASOPHARYNGEAL NEOPLASMS; PEPTIDES; SCAVENGER RECEPTORS, CLASS B; TUMOR MARKERS, BIOLOGICAL;

BIOMARKER; CANCER THERANOSTICS; LIPOPROTEIN NANOCARRIER.; NASOPHARYNGEAL CARCINOMA; SR-B1;

EID: 84880768831     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.6617     Document Type: Article

References (49)

1. Chan AT. Nasopharyngeal carcinoma. Ann Oncol. 2010; 21: vii308-12.
2. Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med. 2007; 9: 1-24.
3. Li F, Guan Y, Chen Z. Proteomics in nasopharyngeal carcinoma. Cell Mol Life Sci. 2008; 65: 1007-12.
4. Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest. 2009; 119: 3626-36.
5. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006; 66: 6225-32.
6. Tao Q, Young LS, Woodman CB, Murray PG. Epstein-Barr virus (EBV) and its associated human cancers--genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci. 2006; 11: 2672-713.
7. Cho WC. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer. 2007; 6: 1.
8. Guigay J. Advances in nasopharyngeal carcinoma. Curr Opin Oncol. 2008; 20: 264-9.
9. Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012; 6: 140-6.
10. Ma BB, Hui EP, Chan AT. Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. Cancer Sci. 2008; 99: 1311-8.
11. Suarez C, Rodrigo JP, Rinaldo A, Langendijk JA, Shaha AR, Ferlito A. Current treatment options for recurrent nasopharyngeal cancer. Eur Arch Otorhinolaryngol. 2010; 267: 1811-24.
12. Razak AR, Siu LL, Liu FF, Ito E, O'Sullivan B, Chan K. Nasopharyngeal carcinoma: the next challenges. Eur J Cancer. 2010; 46: 1967-78.
13. Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol. 2013;25: 50-1.
14. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57-70.
15. Krieger M. Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem. 1999; 68: 523-58.
16. Murao K, Terpstra V, Green SR, Kondratenko N, Steinberg D, Quehenberger O. Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes. J Biol Chem. 1997; 272: 17551-7.
17. Cao WM, Murao K, Imachi H, Yu X, Abe H, Yamauchi A, et al. A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res. 2004; 64: 1515-21.
18. Mooberry LK, Nair M, Paranjape S, McConathy WJ, Lacko AG. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target. 2010; 18: 53-8.
19. Shahzad MM, Mangala LS, Han HD, Lu C, Bottsford-Miller J, Nishimura M, et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia. 2011; 13: 309-19.
20. Su F, Kozak KR, Imaizumi S, Gao F, Amneus MW, Grijalva V, et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A. 2010; 107: 19997-20002.
21. Valacchi G, Sticozzi C, Lim Y, Pecorelli A. Scavenger receptor class B type I: a multifunctional receptor. Ann N Y Acad Sci. 2011; 1229: E1-7.
22. Connelly MA, Williams DL. SR-BI and cholesterol uptake into steroidogenic cells. Trends Endocrinol Metab. 2003; 14: 467-72.
23. Gospodarowicz D, Lui GM, Gonzalez R. High-density lipoproteins and the proliferation of human tumor cells maintained on extracellular matrix-coated dishes and exposed to defined medium. Cancer Res. 1982; 42: 3704-13.
24. Yeagle PL. Modulation of Membrane-Function by Cholesterol. Biochimie. 1991; 73: 1303-10.
25. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Tjonneland A, et al. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 2007; 14: 755-67.
26. Fiorenza AM, Branchi A, Sommariva D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res. 2000; 30: 141-5.
27. Lacko AG, Nair M, Prokai L, McConathy WJ. Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Expert Opin Drug Deliv. 2007; 4: 665-75.
28. Ng KK, Lovell JF, Zheng G. Lipoprotein-Inspired Nanoparticles for Cancer Theranostics. Acc Chem Res. 2011; 44: 1105-13.
29. Zhang ZH, Cao WG, Jin HL, Lovell JF, Yang M, Ding LL, et al. Biomimetic Nanocarrier for Direct Cytosolic Drug Delivery. Angew Chem Int Ed Engl. 2009; 48: 9171-5.
30. Su F, Grijalva V, Navab K, Ganapathy E, Meriwether D, Imaizumi S, et al. HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol Cancer Ther. 2012; 11: 1311-9.
31. Zhang XX, Eden HS, Chen X. Peptides in cancer nanomedicine: Drug carriers, targeting ligands and protease substrates. J Control Release. 2012; 159: 2-13.
32. Yang M, Chen J, Cao WG, Ding LL, Ng KK, Jin HL, et al. Attenuation of nontargeted cell-kill using a high-density lipoprotein-mimicking peptide phospholipid nanoscaffold. Nanomedicine. 2011; 6: 631-41.
33. Yang M, Jin HL, Chen JA, Ding LL, Ng KK, Lin QY, et al. Efficient Cytosolic Delivery of siRNA Using HDL-Mimicking Nanoparticles. Small. 2011; 7: 568-73.
34. Zheng Y, Huang C, Cheng ZY, Chen M. Establishment of Visible Animal Metastasis Models for Human Nasopharyngeal Carcinoma Based on a Far-Red Fluorescent Protein. J Innov Opt Health Sci. 2012; 05: 1250019.
35. Cao G, Garcia CK, Wyne KL, Schultz RA, Parker KL, Hobbs HH. Structure and localization of the human gene encoding SR-BI/CLA-1. Evidence for transcriptional control by steroidogenic factor 1. J Biol Chem. 1997; 272: 33068-76.
36. Bocharov AV, Baranova IN, Vishnyakova TG, Remaley AT, Csako G, Thomas F, et al. Targeting of scavenger receptor class B type I by synthetic amphipathic alpha-helical-containing peptides blocks lipopolysaccharide (LPS) uptake and LPS-induced pro-inflammatory cytokine responses in THP-1 monocyte cells. J Biol Chem. 2004; 279: 36072-82.
37. Witt W, Kolleck I, Fechner H, Sinha P, Rustow B. Regulation by vitamin E of the scavenger receptor BI in rat liver and HepG2 cells. J Lipid Res. 2000; 41: 2009-16.
38. Sahai E. Illuminating the metastatic process. Nat Rev Cancer. 2007; 7: 737-49.
39. Sabnis N, Lacko AG. Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics. Ther Deliv. 2012; 3: 599-608.
40. Li H, Wang D, Zhang H, Kirmani K, Zhao Z, Steinmetz R, et al. Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice. Mol Cancer Ther. 2009; 8: 1692-701.
41. Ganapathy E, Su F, Meriwether D, Devarajan A, Grijalva V, Gao F, et al. D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD. Int J Cancer. 2012; 130: 1071-81.
42. Behrend L, Henderson G, Zwacka RM. Reactive oxygen species in oncogenic transformation. Biochem Soc Trans. 2003; 31: 1441-4.
43. Yang S, Damiano MG, Zhang H, Tripathy S, Luthi AJ, Rink JS, et al. Biomimetic, synthetic HDL nanostructures for lymphoma. Proc Natl Acad Sci U S A. 2013; 110: 2511-6.
44. Jin HL, Chen J, Lovell JF, Zhang ZH, Zheng G. Synthesis and Development of Lipoprotein-Based Nanocarriers for Light-Activated Theranostics. Isr J Chem. 2012; 52: 715-27.
45. Melancon MP, Stafford RJ, Li C. Challenges to effective cancer nanotheranostics. J Control Release. 2012; 164: 177-82.
46. Luo H, Shi J, Jin H, Fan D, Lu L, Wang F, et al. An (125)I-labeled octavalent peptide fluorescent nanoprobe for tumor-homing imaging in vivo. Biomaterials. 2012; 33: 4843-50.
47. Luo H, Yang J, Jin H, Huang C, Fu J, Yang F, et al. Tetrameric far-red fluorescent protein as a scaffold to assemble an octavalent peptide nanoprobe for enhanced tumor targeting and intracellular uptake in vivo. FASEB J. 2011; 25: 1865-73.
48. Yu B, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol. 2010; 27: 286-98.
49. Zhang Z, Chen J, Ding L, Jin H, Lovell JF, Corbin IR, et al. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small. 2010; 6: 430-7